Eli Lilly has opened a formal early access pathway for its investigational obesity drug, retatrutide, following intense pressure from physicians. The company confirmed the program on August 3, 2026, creating a structure for patients who meet specific clinical criteria to request the medication before it receives official FDA approval.
This decision marks a shift in how the company handles compassionate-use requests. Earlier this year, reports surfaced that a single 79-year-old patient gained access to the drug in April, while other clinicians struggled to get responses for their own patients. Several doctors, including those at specialized obesity clinics, reported weeks of silence from the manufacturer when requesting similar access for patients who had not responded to existing treatments like Zepbound.
The new program requires patients to be at least 18 years old, unable to join a clinical trial, and suffering from refractory obesity with multiple serious complications. While criteria details vary slightly by source, the overarching requirement involves demonstrating that standard medical options have failed to produce results. A company spokesperson noted that they are now actively reviewing applications from health care providers.
Simultaneously, Lilly is moving forward with its regulatory path for the drug. Recent phase 3 trial data showed significant weight loss results, with some patients losing over 20 percent of their body weight at 80 weeks. Despite these positive clinical findings, many physicians maintain caution, noting that more safety data is necessary before the drug sees widespread use outside of strictly monitored trial environments. The company expects to submit its formal biologics license application to federal regulators early next year.